Skip to main content
SpringerLink
Log in

Laminin-5 γ2-chain expression and DNA ploidy as predictors of prognosis in endometrial carcinoma

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Expression of the laminin-5 γ2-chain in carcinoma cells has been implicated in tumor invasion. The aim was to investigate the expression and prognostic significance of the In-5 γ2-chain compared with clinicopathological factors and tumor cell DNA ploidy in endometrial carcinoma. Histological specimens from 80 endometrial carcinomas were examined with respect to immunohistochemical In-5 γ2-chain expression and correlated to the clinicopathological characteristics, DNA ploidy, and survival. Sixty-eight of 80 investigated cases were judged to be positive for the In-5 γ2-chain. Ln-5 γ2-chain did not show any correlation to stage, histopathological subtype, grade, and DNA ploidy. In univariate analyses, advanced stage (p<0.001), nonendometrioid carcinoma (p=0.030), low grade (p<0.001), aneuploid tumors (p<0.001), and In-5 γ2-chain expression (p=0.017) were highly associated with poor survival. Aneuploid tumors in combination with strong In-5 γ2-chain expression were significant predictors (p<0.001) of poor prognosis. In multivariate analyses including stage, histopathological subgroup, grade, DNA ploidy, and In-5 γ2-chain expression, all lost their significant prognostic information except for stage (p<0.001) and grade (p<0.05). Ln-5 γ2-chain expression and DNA ploidy both as a single parameter and in combination were demonstrated to be significant prognostic factors in univariate analysis. However, stage and grade provided more useful clinical information beyond histopathological subgroup, DNA ploidy, and In-5 γ2-chain expression. The results also indicate that In-5 γ2-chain expression is upregulated during the progression of endometrial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pettersson, F. (ed.) (1994). Annual Report on the Results of Treatment in Gynecological Cancer, 1987–93. FIGO, Stockholm, Vol. 22.

    Google Scholar 

  2. Geisler, J.P., Wiemann, M.C., Zhou, Z., Miller, G.A. and Geisler, H.E. (1996). p53 as a prognostic indicator in endometrial cancer. Gynecol. Oncol. 61(2):245–248.

    Article  PubMed  CAS  Google Scholar 

  3. Strang, P., Nordstom, B., Nilsson, S., Bergstrom, R. and Tribukait, B. (1996). Mutant p53 protein as a predictor of survival in endometrial carcinoma. Eur. J. Cancer 32A(4):598–602.

    Article  PubMed  CAS  Google Scholar 

  4. Salvesen, H.B., Iversen, O.E. and Akslen, L.A. (1999). Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J. Clin. Oncol. 17(5):1382–1390.

    PubMed  CAS  Google Scholar 

  5. Geisler, J.P., et al. (1999). MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol. Oncol. 75(3):432–436.

    Article  PubMed  CAS  Google Scholar 

  6. Nordstrom, B., Strang, P., Bergstrom, R., Nilsson, S. and Tribukait, B. (1996). A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer 78(9):1942–1951.

    Article  PubMed  CAS  Google Scholar 

  7. Stendahl, U., Wagenius, G., Strang, P. and Tribukait, B. (1988). Flow cytometry in invasive endometrial carcinoma. Correlations between DNA content S-phase rate and clinical parameters. In Vivo 2(2):123–127.

    PubMed  CAS  Google Scholar 

  8. Lundgren, C., et al. (2002). Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int. J. Gynecol. Cancer 12(1):110–118.

    Article  PubMed  Google Scholar 

  9. Biesterfeld, S., Leitloff, M., Rath, W. and Schroder, W. (2001). DNA image cytometry in the differential diagnosis of endometrial hyperplasia and adenocarcinoma. Anal. Quant. Cytol. Histol. 23(2):123–128.

    PubMed  CAS  Google Scholar 

  10. Pyke, C., et al. (1994). The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am. J. Pathol. 145(4):782–791.

    PubMed  CAS  Google Scholar 

  11. Salo, S., et al. (1999). Laminin-5 promotes adhesion and migration of epithelial cells: identification of a migration-related element in the gamma2 chain gene (LAMC2) with activity in transgenic mice. Matrix Biol. 18(2):197–210.

    Article  PubMed  CAS  Google Scholar 

  12. Giannelli, G. and Antonaci, S. (2000). Biological and clinical relevance of laminin-5 in cancer. Clin. Exp. Metastasis 18(6):439–443.

    Article  PubMed  CAS  Google Scholar 

  13. Gagnoux-Palacios, L., et al. (2001). The short arm of the laminin gamma2 chain plays a pivotal role in the incorporation of laminin 5 into the extracellular matrix and in cell adhesion. J. Cell Biol. 153(4):835–850.

    Article  PubMed  CAS  Google Scholar 

  14. Pyke, C., et al. (1995). Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res. 55(18):4132–4139.

    PubMed  CAS  Google Scholar 

  15. Sordat, I., et al. (1998). Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J. Pathol. 185(1):44–52.

    Article  PubMed  CAS  Google Scholar 

  16. Lenander, C., et al. (2001). Laminin-5 gamma 2 chain expression correlates with unfavorable prognosis in colon carcinomas. Anal. Cell Pathol. 22(4):201–209.

    PubMed  CAS  Google Scholar 

  17. Kainulainen, T., et al. (1997). Altered distribution and synthesis of laminin-5 (kalinin) in oral lichen planus, epithelial dysplasias and squamous cell carcinomas. Br. J. Dermatol. 136(3):331–336.

    Article  PubMed  CAS  Google Scholar 

  18. Skyldberg, B., et al. (1999). Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl. Cancer Inst. 91(21):1882–1887.

    Article  PubMed  CAS  Google Scholar 

  19. Fukushima, N., Sakamoto, M. and Hirohashi, S. (2001). Expression of laminin-5-gamma-2 chain in intraductal papillary-mucinous and invasive ductal tumors of the pancreas. Mod. Pathol. 14(5):404–409.

    Article  PubMed  CAS  Google Scholar 

  20. Hellman, K., et al. (2000). Cancer of the vagina: laminin-5 gamma2 chain expression and prognosis. Int. J. Gynecol. Cancer 10(5):391–396.

    Article  PubMed  Google Scholar 

  21. Yamamoto, H., Itoh, F., Iku, S., Hosokawa, M. and Imai, K. (2001). Expression of the gamma(2) chain of laminin-5 at the invasive front is associated with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Clin. Cancer Res. 7(4):896–900.

    PubMed  CAS  Google Scholar 

  22. Nordstrom, B., et al. (2002). Laminin-5 gamma 2 chain as an invasivity marker for uni- and multifocal lesions in the lower anogenital tract. Int. J. Gynecol. Cancer 12(1):105–109.

    Article  PubMed  Google Scholar 

  23. Nordemar, S., et al. (2001). Laminin-5 as a predictor of invasiveness in cancer in situ lesions of the larynx. Anticancer Res. 21(1B):509–512.

    PubMed  CAS  Google Scholar 

  24. Hao, J., et al. (2001). Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer. Am. J. Pathol. 158(3):1129–1135.

    PubMed  CAS  Google Scholar 

  25. Martin, K.J., et al. (1998). Down-regulation of laminin-5 in breast carcinoma cells. Mol. Med. 4(9):602–613.

    PubMed  CAS  Google Scholar 

  26. Sobin, L. (ed.) (1978). A Coded Compendium of Internanational Histological Classifications of Tumours, 11th ed. World Health Organization, Geneva.

    Google Scholar 

  27. FIGO (1989). FIGO stages–1988 revisions: Vulva, ovary, corpus. Gynecol. Oncol. 35:125–127.

    Article  Google Scholar 

  28. Gaub, J.A. and Zetterberg, A. (1965). Quantitative cytochemical aspects of a combined Feulgen naphtol-yellow-s staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells. Exp. Cell Res. 92:323–332.

    Article  Google Scholar 

  29. Steinbeck, R.G., Auer, G.U. and Zetterberg, A.D. (1999). Reliability and significance of DNA measurements in interphase nuclei and division figures in histological sections. Eur. J. Cancer 35(5):787–795.

    Article  PubMed  CAS  Google Scholar 

  30. Auer, G. and Tribukait, B. (1980). Comparative single cell and flow DNA analysis in aspiration biopsies from breast carcinomas. Acta Pathol. Microbiol. Scand. [A] 88(6):355–358.

    CAS  Google Scholar 

  31. Hellstrom, A., Hue, J., Silfverswärd, C. and Auer, G. (1994). DNA-ploidy and mutant p53 overexpression in primary fallopian tube cancer. Int. J. Gynecol. Cancer 4:408–413.

    Article  PubMed  Google Scholar 

  32. Auer, G.U., Caspersson, T.O. and Wallgren, A.S. (1980). DNA content and survival in mammary carcinoma. Anal. Quant. Cytol. 2(3):161–165.

    PubMed  CAS  Google Scholar 

  33. Nordstrom, B., Strang, P., Lindgren, A., Bergstrom, R. and Tribukait, B. (1996). Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int. J. Gynecol. Pathol. 15(3):191–201.

    Article  PubMed  CAS  Google Scholar 

  34. Zaino, R.J., Davis, A.T., Ohlsson-Wilhelm, B.M. and Brunetto, V.L. (1998). DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int. J. Gynecol. Pathol. 17(4):312–319.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynaecologic Oncology, Radiumhemmet, Karolinska Hospital, S 171-76, Stockholm, Sweden

    C. Lundgren MD, B. Frankendal & B. Nordström

  2. Department of Pathology and Cell Analysis, Medical Biochemistry and Biophysics, Karolinska Hospital and Institute, S 171-76, Stockholm, Sweden

    C. Silfverswärd & G. Auer

  3. Department of Cancer Epidemiology, Medical Biochemistry and Biophysics, Karolinska Hospital and Institute, S 171-76, Stockholm, Sweden

    B. Nilsson

  4. Department of Matrix Biology, Medical Biochemistry and Biophysics, Karolinska Hospital and Institute, S 171-76, Stockholm, Sweden

    K. Tryggvason

Authors
  1. C. Lundgren MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Frankendal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Silfverswärd
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Tryggvason
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Auer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Nordström
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Lundgren MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lundgren, C., Frankendal, B., Silfverswärd, C. et al. Laminin-5 γ2-chain expression and DNA ploidy as predictors of prognosis in endometrial carcinoma. Med Oncol 20, 147–155 (2003). https://doi.org/10.1385/MO:20:2:147

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:20:2:147

Key Words

Search

Navigation